MegaRobo Technologies, a Chinese start-up that uses artificial intelligence and robotics in life sciences research, has raised $300 million in a funding round led by Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital. The six-year-old company is the latest start-up from the pharmaceutical industry to capitalize on a jump in investor interest in the sector after the COVID-19 pandemic. MegaRobo, whose products include a COVID-19 testing solution, said on Wednesday it plans to use the fresh funds to fund research and development, increase capacity and expand its presence into new international markets.